Group 1 - The recent appreciation of the Renminbi (RMB) against the US dollar has reached a 14-month high, with offshore RMB surpassing 7.02 and onshore RMB exceeding 7.03 [1][3] - The appreciation is driven by two main factors: external environmental changes and seasonal domestic demand, which have combined to initiate a sustained upward trend in the RMB [4][8] - The weakening of the US dollar, particularly after the Federal Reserve announced interest rate cuts, has diminished the dollar's attractiveness, leading to a relative appreciation of other currencies, including the RMB [6][8] Group 2 - The year-end demand for currency exchange has significantly contributed to the RMB's appreciation, as many companies need to convert USD to RMB for year-end payments [8][10] - The issuance of RMB-denominated bonds by foreign entities, such as Kazakhstan and Indonesia, indicates increasing international recognition of the RMB, supporting its long-term appreciation [12][14] - The RMB's appreciation has mixed effects: export companies face profit pressures, while import companies and consumers benefit from lower costs for foreign goods [16][22] Group 3 - Export companies are struggling with the rapid appreciation, as their USD-denominated orders yield less RMB upon conversion, impacting their profit margins [18][20] - In contrast, import companies and consumers enjoy lower prices for imported goods, making travel and overseas education more affordable [24][26] - The RMB's appreciation can help stabilize domestic prices and align with national strategies to boost consumption and economic growth [26][40] Group 4 - Market consensus suggests that the RMB will maintain a strong position in the short term, influenced by the ongoing weakness of the US dollar and year-end exchange demands [29][31] - The central bank is actively managing the exchange rate to prevent excessive volatility, making it challenging for the RMB to break through the 7.0 mark [31][33] - Companies are encouraged to adapt to these changes by utilizing hedging tools to mitigate risks associated with currency fluctuations [35][37] Group 5 - The ongoing appreciation of the RMB reflects broader trends in the global financial market and the internationalization of the currency [38][41] - Companies are advised to enhance their risk management capabilities and core competitiveness in response to currency fluctuations [40][41]

证券代码：603883 证券简称：老百姓 公告编号：2025-073 关于归还临时补充流动资金的募集资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 老百姓大药房连锁股份有限公司 2025年12月25日，公司已归还10,000万元至募集资金专用账户，并将上述募 集资金的归还情况通知公司募集资金持续督导机构高盛（中国）证券有限责任公 司及保荐代表人。 | 本次归还募集资金金额（万元） | 10,000 | | --- | --- | | 尚未归还的募集资金金额（万元） | 0 | | 是否已归还完毕 | √是□否 | | 归还完毕的具体时间 | 2025年12月25日 | 特此公告。 截至 2025 年 12 月 25 日，公司已累计归还临时补充流动资金的闲置 募集资金人民币 10,000 万元。 一、募集资金临时补充流动资金情况 老百姓大药房连锁股份有限公司（以下简称"公司"）于2025年10月28日召 开第五届董事会第十一次会议，审议通过了《关于使用部分闲置募集资金暂时补 充流动资金的议案》，同意公 ...

| 日期 | 证券代 | 证券简 质押笔 | 无限售股份质押数里 | 有限售股份质押数里 | A股总股本 | 质押比例 | | --- | --- | --- | --- | --- | --- | --- | | 唱 | | 都 载 | (万) | (万) | (万) | (%) | | 20251219 603883 | | 老自姓 8 | 23455.04 | 0.00 | 75889.02 | 30.91 | 中国经济网北京12月25日讯 老百姓（603883）(603883.SH)昨晚披露关于控股股东股票质押的公告称，公司控股股 东老百姓医药集团有限公司（以下简称"医药集团"）持有公司股份数量为180,453,475股，占公司总股本比例为 23.78%；累计质押股份数量为114,140,000股（含本次质押），占其所持股份比例为63.25%，占公司总股本比例为 15.04%。 控股股东及一致行动人（医药集团与陈秀兰）合计持有公司股份数量为194,019,173股，占公司总股本比例为 25.57%；累计质押股份数量为114,140,000股（含本次质押），占其所持股份比例为58.83%，占公司总股本比 ...

Core Viewpoint - The domestic chain pharmacy industry is entering a period of negative growth, with a significant reduction in the number of pharmacies and a shift from rapid expansion to a focus on value enhancement and health services [2][3][11] Industry Overview - By Q1 2025, the total number of pharmacies in China is expected to fall below 700,000, with a net decrease of approximately 3,000 stores in a single quarter, indicating a widespread "store closure wave" [2] - The overall market size for pharmaceuticals is projected to reach 2.03 trillion yuan in 2024, but the growth rate is only 0.9%, with a forecasted decline to 1.97 trillion yuan in 2025 [2] Company Performance - Major chain pharmacies are experiencing divergent performance: Dazhenglin reported a net profit of 1.081 billion yuan in the first three quarters of 2025, up 25.97% year-on-year; Yifeng Pharmacy's net profit reached 1.225 billion yuan, a 10.27% increase; while Yixintang faced a decline with a net profit of 269 million yuan, down 8.17% [2] Store Closure Trends - Predictions indicate that the number of pharmacy closures in 2025 could reach between 50,000 and 100,000, marking a shift from the previous era of aggressive expansion to a focus on operational efficiency [3][4] - The industry is expected to return to a more reasonable scale of around 500,000 pharmacies, similar to levels seen in 2018 [4] Market Dynamics - The closure wave is driven by oversupply and increased regulatory pressures, with a significant rise in the proportion of non-pharmaceutical sales, which reached 34.6% in 2025, up 5.2 percentage points from 2024 [5] - The market share of the top ten pharmacy brands increased to 58% in Q3 2025, reflecting a growing concentration in the industry as smaller players exit [5] Business Model Evolution - The franchise model is becoming a key strategy for leading pharmacy chains to expand market share, with significant increases in franchise store openings reported [6] - The industry is transitioning from a focus on selling drugs to providing health services, with a notable shift towards a "sell health" approach [6][7] Professionalization and Service Enhancement - Professionalization is identified as a core development direction, with leading companies adopting innovative drug and DTP pharmacy models to enhance service delivery [7] - Community pharmacies are increasingly focusing on chronic disease management, with a significant percentage of patients expressing a desire for medication guidance and health management services [8] Diversification and Digital Transformation - Leading pharmacies are diversifying their offerings to include health-related products and services, transforming into comprehensive health experience hubs [9] - The integration of online and offline channels is accelerating, with significant growth in new retail segments and contributions from O2O channels [9] Future Outlook - Despite current challenges, industry experts believe that the long-term trend for the chain pharmacy sector remains positive, driven by supply-side adjustments and demand recovery [10] - The future of pharmacies is expected to focus on building a diversified health service ecosystem, aligning with national health strategies and enhancing both social and economic benefits [10][11]

Core Viewpoint - The Commercial Health Insurance Innovative Drug Directory aims to provide a list of high-value innovative drugs that exceed basic medical insurance coverage, effective from January 1, 2026 [1][2]. Group 1: Overview of the Innovative Drug Directory - The directory includes 19 drugs focusing on three key areas: high-priced cancer treatments (5 Car-T cell therapy drugs), rare disease medications, and new targeted therapies for severe cancers [1]. - The directory is intended for reference by commercial health insurance and medical mutual aid systems, highlighting the importance of these drugs for patients with limited treatment options [1]. Group 2: Policy Implications - Drugs listed in the directory are not eligible for reimbursement under basic medical insurance, but the National Healthcare Security Administration has implemented a "three exclusions" policy to facilitate their use in hospitals [2]. - This policy alleviates concerns for hospitals regarding the use of innovative drugs, allowing for direct prescription and reimbursement through commercial insurance, thus bypassing previous complexities [2]. Group 3: Insurance Product Adaptation - Some commercial insurance products, such as certain惠民保 plans, have begun to incorporate drugs from the directory, offering increased reimbursement rates for hospital use of these drugs [2]. - Insurance companies are currently assessing how to integrate the directory's drugs into existing medical insurance products, with some already including specific innovative drugs as optional or mandatory coverage [3]. Group 4: Consumer Guidance - Consumers are advised to carefully review insurance contracts for coverage details, including specific drug lists, reimbursement rates, and any limitations on pharmacies or hospitals [4]. - Understanding the reimbursement process for innovative drugs is crucial, as it often involves specific purchasing locations, prescriptions from specialists, and prior authorization from insurance companies [4]. - Consumers should balance the cost of premiums with the level of coverage provided, considering personal health conditions and financial capabilities when deciding on insurance products that include innovative drug coverage [5].

没过几天，镇干部、施工方和我被请到一起开会，巡察组的同志就坐在我旁边。补偿款怎么算？补的地 选在哪儿？修水坝按啥标准？问题被一一摆上台面。最终方案清清楚楚：按今年邻地租金标准补偿我 350元；将村东头0.42亩机动地划拨给我；水坝结构按设计图纸复原，来年开春由镇里验收。白纸黑字 按上红手印，我这颗悬了几个月的心终于踏实了。 巡察组撤点前专门来回访。我领他们到地头，新修的挡水坝把水拢得妥妥帖帖，再也不用担心稻子抽穗 时缺水了。补偿款早已到账，补地协议也在村务公开栏里张贴公示。 守着田却种不了地，你说这心里是啥滋味？去年秋收刚过，村里修挡水坝，施工队一铲子下去，把我家 0.42亩口粮田并入了集体灌溉渠。地没了，稻茬还在地里撅着，看着实在揪心。 为这事儿我没少费心。找村干部，答复是"等镇上协调"；去镇里，他们摆手说"归水务局管"；问水务 局，得到的回复是"责任得现场认定"……这事儿像皮球一样被踢来踢去快一年，我的心也渐渐凉了。 转机出现在巡察组进驻之后。今年6月份，我听说市委巡察组进驻我们镇了，拿着土地承包证就找上了 门。"推诿扯皮伤民心，这个问题我们必须督促解决。"当天下午，他们就带着测量仪下了地，泥巴糊了 半裤 ...

Core Viewpoint - The announcement reveals that the controlling shareholder, Lao Bai Xi Medicine Group, has pledged 14 million shares of Lao Bai Xi Pharmacy, which raises concerns about the company's financial stability and stock performance [1] Share Pledge Situation - The total number of shares pledged by the controlling shareholder amounts to 114 million, representing 63.25% of their holdings and 15.04% of the company's total share capital [1][2] - The pledge is intended to meet the operational needs of the medicine group, which claims to have the ability to repay the funds, with repayment sources including dividends from the listed company and self-raised funds [2][3] Future Pledge and Reduction Plans - In the next six months, 12.35 million shares are set to mature, accounting for 6.84% of the controlling shareholder's holdings and 1.63% of the company's total shares, with a corresponding financing amount of 100 million [3] - The medicine group plans to reduce its holdings by 18.11 million shares between June 20 and July 30, 2025, at a price range of 17.60 to 21.55 yuan per share, totaling approximately 341 million [4] Financial Performance - Recent financial results show that the company experienced a revenue decline of 0.36% year-on-year in 2024, with a net profit drop of 44.13% [5] - For the first three quarters of 2025, both revenue and net profit continued to decline, with decreases of 1% and 16.11%, respectively [5] - The company's stock price has fallen over 70% from its peak of 53.14 yuan per share in 2020, closing at 15.26 yuan per share with a total market capitalization of 11.58 billion [5]

Group 1 - The controlling shareholder of the company, Lao Bai Xi Medicine Group Co., Ltd., holds approximately 180 million shares, accounting for 23.78% of the total share capital [1] - The total number of pledged shares by the controlling shareholder is about 114 million, representing 63.25% of the shares held and 15.04% of the total share capital [1] - The company’s revenue composition for the first half of 2025 indicates that retail pharmacy accounts for 81.81%, franchise and alliance distribution for 17.26%, and others for 0.93% [1] Group 2 - The company's market capitalization is currently 11.6 billion yuan [2]

证券代码：603883 证券简称：老百姓 公告编号：2025-072 被质押股份不存在被用作重大资产重组业绩补偿等事项的担保或其他保障用途情 老百姓大药房连锁股份有限公司 关于控股股东股票质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： ●老百姓大药房连锁股份有限公司（以下简称"公司"）控股股东老百姓医药集 团有限公司（以下简称"医药集团"）持有公司股份数量为 180,453,475 股，占公司 总股本比例为 23.78%；累计质押股份数量为 114,140,000 股（含本次质押），占其所 持股份比例为 63.25%，占公司总股本比例为 15.04%。控股股东及一致行动人（医药集 团与陈秀兰）合计持有公司股份数量为 194,019,173 股，占公司总股本比例为 25.57%； 累计质押股份数量为 114,140,000 股（含本次质押），占其所持股份比例为 58.83%， 占公司总股本比例为 15.04%。 一、上市公司股份质押 公司于 2025 年 12 月 24 日获悉控股股东医药集团所持有 ...

12月24日，国务院台办举行例行新闻发布会。有记者问：对于大陆方面揭批民进党当局打着"信任""繁 荣"的幌子滥施"金元外交"。台外事部门称，这是推动国际共荣发展的合作理念。请问发言人对此有何 评论？ 发言人彭庆恩表示，民进党当局口中所谓"以价值为本"，实质是"以'台独'为本"，为了谋"独"蓄意煽动 意识形态对立对抗；所谓"以人民福祉为核心"，实则是"以人民福祉为贡品"，挥霍台湾老百姓的血汗钱 换取所谓"国际空间"，卑鄙无耻。"台独"是走不通的绝路，无论民进党当局如何处心积虑搞小动作，都 改变不了台湾是中国一部分的事实，撼动不了国际社会坚持一个中国原则的格局。 ...